--News Direct--

By Johnny Rice, Benzinga

Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a biotechnology company developing drug candidates currently focused on kidney disease. The innovative treatments may have vast potential outside of the specifics of kidney disease as well.

Currently, the company has two treatments in development: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI-494, for treatment of acute kidney injury.

The latter recently passed through a new round of preclinical trials. The results were described as “very encouraging” by a leading expert in the field of AKI (acute kidney injury) research.

Learn more here: Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells

Watch the video here:

This article was originally published on Benzinga here.

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Anne Marie Fields - Stern Investor Relations

+1 212-362-1200

annemarie.fields@sternir.com

https://unicycive.com/

View source version on newsdirect.com: https://newsdirect.com/news/unicycive-this-biotech-company-receives-promising-results-from-new-trial-965853033